Posts

7 days in healthcare (September 12th-18th, 2022)

 

Summary

From the point of view of biomedicine, immunotherapy (in colon cancer) and CAR-T therapies (in lupus) continue to expand their therapeutic possibilities. Advances against infections for resistant bacteria. Will there ever come a time when cancer can be diagnosed by a simple blood test? This possibility does not seem very remote, according to papers presented at the meeting of the European Society of Medical Oncology.

Regarding Global Health, an important work directed by Jeffrey Sachs and published by The Lancet on the delays and errors of both governments and the WHO in dealing with the covid pandemic, which could have produced 17.7 million of  deaths, many of them preventable.

Regarding international health policy, the WHO says that the end of the covid pandemic may be in sight, although at the same time a new variant (BJ.1) of covid is evident in Europe. Important debate in Europe (Scotland and France) on euthanasia and assisted death. The French Ethics Committee opens the door to this possibility. The financing of the American FDA was questioned, due to its great economic dependence on the pharmaceutical industry. Biden launches a speech commemorating Kennedy’s in 1962 when he decided to go to the Moon, but this time oriented towards the fight against cancer.

If we talk about national health policy (Spain), the PDeCAT presents an amendment to the entire equity law, which it accuses of interfering in regional powers and of confusing agreement with privatization. Surprising statements from the Ministry of Health in a parliamentary response, saying that its functions in relation to the waiting lists are only to inform and monitor, as if it did not have the possibility of signing agreements with the communities to address this problem or of launching other actions. Concern, there are even demonstrations in the street, of the relatives of the elderly admitted to residences. The Community of Madrid announces that it will reduce the waiting lists by half. Although we would like it not to be the case this time, this announcement is preceded by other similar ones from different governments, which always came to nothing in terms of effectiveness. The search for solutions by the Ministry of Finance to the MUFACE model, highly impacted by inflation, seems to recognize its underfinancing.

In the field of companies, from the international point of view, important success for Sanofi, with its new vaccine against bronchiolitis. In Spain, important corporate movements in Korian, HM Hospitales, Miranza and Ribera.

Biomedicine

Global Health

International health policy

National health policy

Companies

 

7 days in healthcare (6th-12th June, 2022)

 

Summary

From the point of view of biomedicine, the article in the journal Cell stands out, in which MIT researchers design a complete functional map of genes in human cells. Also the possibilities of liquid biopsy, which will make it possible to diagnose cancers at an early stage through a simple blood test. It is also necessary to highlight the controversy over the transmission of monkeypox, some say that the transmission could be aerial, while the CDC denies it. This is important in terms of vaccination strategy.

As far as Global Health is concerned, the humanitarian problems of the Ukraine war should be highlighted, which will not only be local but global.

Regarding international health policy, it is worth highlighting the Health Affairs article that shows that mortality from covid is higher in counties with a Republican vote than in those with a Democratic vote. Incredible conclusion, although this can be explained by a greater rejection of masks, social distance and vaccination in Republican environments. Health and its preventive orientation declared a priority by Macron. We will see what this translates into in practice.

If we talk about national health policy (Spain), it should be mentioned that 15 new CAR-T centers are approved in several hospitals. Impressive and accurate title of a talk by Rafael Bengoa: “SNS: 500,000 competent professionals in an incompetent model.” It rightly puts the emphasis on management and organization. This contrasts with the poverty and lack of news and prioritization of the programs of both the PP and the PSOE in the Andalusian elections. The PP program introduces the nonsense of making the 9,000 hired by the public health companies statutory, one of the successes of the PSOE in health. As for the PSOE program, it is a very long program, without any prioritization, and full of reflections against collaboration with the private sector, as if the so-called “privatization” were the problem of the system.

At the corporate level, the promising advances of BioNTech in pancreatic cancer and AstraZeneca-Daiichi in breast cancer should be noted.

Biomedicine

Global Health

International health policy

National health policy

Companies